丹槐银屑浓缩丸对豚鼠银屑病样模型病理形态及组织TNF-α，TGF-β_1的影响
|
摘要
银屑病是一种常见并易复发的慢性炎症性疾病,病因及发病机制尚未完全明了。现代研究证明与遗传缺陷、免疫功能障碍、神经介质的变化、细胞增殖与凋亡异常、微循环障碍、代谢和内分泌紊乱、神经精神功能障碍等多种因素有关,是遗传因素与环境因素等多种因素相互作用的多基因遗传病。目前西药治疗银屑病疗效可靠但毒副作用较大,且停药易复发。中医药治疗银屑病疗效可靠,毒副作用小,已成为现在临床和科研的热点。
银屑病是多基因遗传背景下的机体免疫失常的疾病,免疫介导是疾病的主要发生机制。在病理生理上表现为角质形成细胞的在免疫因子的作用或介导下过度角化和角化不全,基底层迂曲变形,棘层增厚,颗粒层变薄或消失,真皮浅层毛细血管增生,炎性细胞浸润等。临床上丹槐银屑浓缩丸用于血热型银屑病(寻常型)的治疗,疗效可靠。本课题的目的是研究中药丹槐银屑浓缩丸对豚鼠银屑病样模型的表皮病理变化及银屑病相关免疫因子的影响。我们通过制备豚鼠银屑病样模型,设空白组、模型组、西药和成药对照组以及高、中、低三个剂量组,考察丹槐银屑浓缩丸对银屑病过度角化和角化不全抑制作用和对银屑病相关免疫因子的调节作用以及这些作用与剂量的依赖关系。结果显示丹槐银屑浓缩丸对豚鼠银屑病样模型有明显的治疗作用。本实验显示丹槐银屑浓缩丸中、低剂量组疗效优于成药对照组而与西药对照组相当。由此推断,丹槐银屑浓缩丸中、低剂量可能通过抑制表皮细胞增殖与促进其分化,抑制细胞炎症因子,参与抗炎与免疫调节过程来发挥治疗作用的。而高剂量作用却不明显,其机理有待进一步研究。该研究的成果为丹槐银屑浓缩丸治疗银屑病的临床疗效作了有力的验证和为丹槐银屑浓缩丸治疗银屑病临床方案的合理化和优化提供了有力的实验依据。
Psoriasis is a chronic inflammatory dermatosis characterized by erythema and generous scales. As a common disease throughout the world it does great harm to patients’physical and mental health. The aetiology of psoriasis is known incompletely and the curative effect is not very satisfatory. But modern researches have demonstrate that Psoriasis has greatly something to do with heredity, immunologic function dysfunction, infection, inflammation, neuromediator, endocrine, cell proliferation and apoptosis, microcirculation disorder, metabolism, nerve and psyche ,and so on. Psoriasis is the interactive result of genetic factor and environment factor. So far western medicine have certain curative efect on psoriasis but not can do without toxic and side-effect, furthermore, relatpseing is frequent after drug withdrawal. So herb therapy on psoriasis is a prevalence in china and in the world because of the true cure and lower toxic and lower side-effect than western medicine.
Psoriasis is a disease of immune disturbance under polygenic inheritance. The fundamental mechanism is the immune incorreted interference. Modern researches have established hyperkeratinization and parakeratosis of keratinocytes and the hyperplasia of the capillary vessel in the dermis as the fundamental pathological changes. Clinically, we apply DHYXNSW to treating Xuerexing-psoriasis (psoriasis vulgaris),and the effect is significant. This study is aimed to observe the effet of DHYXNSW on pathological changes and immune factors associated with psoriasis of guinea pig model of psoriasis-like skin. Through establishing two control groups of Methotrexate and FFQDJN and establishing high, medium and low dose groups of DHYXNSW to treating guinea pig of psoriasis-like model, we investigate the inhibition of psoriatic hyperkeratosis and parakeratosis, and mediating of immune factors of guinea pig of psoriasis-like model and their dose-dependent effects. The results show that DHYXNSW have significant therapeutic effect on psoriasis-like model of guinea pig, and the effects are not significantly correlated with the dose. This study demonstrates that the therapeutic effects of medium, low dose group of DHYXNSW are better than the FfqdJN group but are as good as the Western medicine group in inhibiting the epidermal cell proliferation and promoting their differentiation,inhibiting cytokine involved in inflammatory and immune processes. Effect at high doses is close to FfqdJN group but no better than medium and low dose group, the mechanism needs further study. The study's results of DHYXNSW efffect of the treatment of psoriasis-like model provides with a powerful experimental evidence to the treatment of psoriasis in clinic and play a significantcant role in the rationalization and optimization of clinical programs.
银屑病是多基因遗传背景下的机体免疫失常的疾病,免疫介导是疾病的主要发生机制。在病理生理上表现为角质形成细胞的在免疫因子的作用或介导下过度角化和角化不全,基底层迂曲变形,棘层增厚,颗粒层变薄或消失,真皮浅层毛细血管增生,炎性细胞浸润等。临床上丹槐银屑浓缩丸用于血热型银屑病(寻常型)的治疗,疗效可靠。本课题的目的是研究中药丹槐银屑浓缩丸对豚鼠银屑病样模型的表皮病理变化及银屑病相关免疫因子的影响。我们通过制备豚鼠银屑病样模型,设空白组、模型组、西药和成药对照组以及高、中、低三个剂量组,考察丹槐银屑浓缩丸对银屑病过度角化和角化不全抑制作用和对银屑病相关免疫因子的调节作用以及这些作用与剂量的依赖关系。结果显示丹槐银屑浓缩丸对豚鼠银屑病样模型有明显的治疗作用。本实验显示丹槐银屑浓缩丸中、低剂量组疗效优于成药对照组而与西药对照组相当。由此推断,丹槐银屑浓缩丸中、低剂量可能通过抑制表皮细胞增殖与促进其分化,抑制细胞炎症因子,参与抗炎与免疫调节过程来发挥治疗作用的。而高剂量作用却不明显,其机理有待进一步研究。该研究的成果为丹槐银屑浓缩丸治疗银屑病的临床疗效作了有力的验证和为丹槐银屑浓缩丸治疗银屑病临床方案的合理化和优化提供了有力的实验依据。
Psoriasis is a chronic inflammatory dermatosis characterized by erythema and generous scales. As a common disease throughout the world it does great harm to patients’physical and mental health. The aetiology of psoriasis is known incompletely and the curative effect is not very satisfatory. But modern researches have demonstrate that Psoriasis has greatly something to do with heredity, immunologic function dysfunction, infection, inflammation, neuromediator, endocrine, cell proliferation and apoptosis, microcirculation disorder, metabolism, nerve and psyche ,and so on. Psoriasis is the interactive result of genetic factor and environment factor. So far western medicine have certain curative efect on psoriasis but not can do without toxic and side-effect, furthermore, relatpseing is frequent after drug withdrawal. So herb therapy on psoriasis is a prevalence in china and in the world because of the true cure and lower toxic and lower side-effect than western medicine.
Psoriasis is a disease of immune disturbance under polygenic inheritance. The fundamental mechanism is the immune incorreted interference. Modern researches have established hyperkeratinization and parakeratosis of keratinocytes and the hyperplasia of the capillary vessel in the dermis as the fundamental pathological changes. Clinically, we apply DHYXNSW to treating Xuerexing-psoriasis (psoriasis vulgaris),and the effect is significant. This study is aimed to observe the effet of DHYXNSW on pathological changes and immune factors associated with psoriasis of guinea pig model of psoriasis-like skin. Through establishing two control groups of Methotrexate and FFQDJN and establishing high, medium and low dose groups of DHYXNSW to treating guinea pig of psoriasis-like model, we investigate the inhibition of psoriatic hyperkeratosis and parakeratosis, and mediating of immune factors of guinea pig of psoriasis-like model and their dose-dependent effects. The results show that DHYXNSW have significant therapeutic effect on psoriasis-like model of guinea pig, and the effects are not significantly correlated with the dose. This study demonstrates that the therapeutic effects of medium, low dose group of DHYXNSW are better than the FfqdJN group but are as good as the Western medicine group in inhibiting the epidermal cell proliferation and promoting their differentiation,inhibiting cytokine involved in inflammatory and immune processes. Effect at high doses is close to FfqdJN group but no better than medium and low dose group, the mechanism needs further study. The study's results of DHYXNSW efffect of the treatment of psoriasis-like model provides with a powerful experimental evidence to the treatment of psoriasis in clinic and play a significantcant role in the rationalization and optimization of clinical programs.
引文
[1] Gaylarde PM,etal.Psoriasiform changes in guinea pig skin from propranolol.[J] Clinical and Experimental Dermatology.1978,3:157-160
[2] Baker BS. Brent L. Valdimarsson H. Powles AV. al-lmara L. Walker M. Fry L. ls epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?. [J] Br J Dermatol. 1992 Feb; 126(2):105-10.
[3]冯晓刚,耿春霞,吴明明.银屑病中医病因病机文献研究. [J]现代中西医结合杂志. 2009 18 (8):932
[4]李元文,张丰川.专科专病名医临证经验丛书皮肤病. [J]皮肤病. 2002:270-340.
[5]金起凤.消银解毒汤治疗银屑病58例疗效观察.[J]辽宁中医杂志.1983,(6):29-30
[6]周鸣岐.辨证分型治疗银屑病802例.[J]中医杂志.1989,30(5):42
[7]张志礼.皮肤病临床经验四.中国医药科技出版社.2001,115.
[8]顾伯华.外科经验集.[M]上海:上海人民出版社.1977,252.
[9]丁履伸,赵绚德.银屑病的中医治疗.[J]山东中医学院学报.1980,4(4):47-49.
[10]徐国强.银屑病中医证治浅析.[J]世界中医药.2010,5(1):56-57
[11]钟金宝,李仰琪,凉颜酶.中医辨证治疗寻常银屑病96例. [J]江西中医药.2007,38(8):33-34.
[12]王芳.运用清热凉血法治疗血热型进行期寻常型银屑病46例的临临床观察.[J]北京中医.2005,24(5):301-302.
[13]刘靖,查旭山.凉血消银汤治疗进行习期寻常型银屑病(血热证)32例疗效观察.[J]新中医.2006,38(8):28-29.
[14]张建平,董鸿智.消银汤治疗寻常型银屑病血热证52例.[J]陕西中医学院学报.2007,30(1):33,34.
[15]熊波.从瘀证论治稳定期银屑病50例.[J]湖北中医杂志.2004,26(3):44.
[16]刘朝霞.以健脾益肾治疗寻常型静止期银屑病.[J]新疆中医药.2006,24(5):46-47.
[17]周淑维.庄国康教授治疗银屑病经验.[J]中国中西医结合皮肤性病学杂志.2004,3(1):37.
[18]陈丽红.消银汤治疗寻常型银屑病56例.[J]福建中医药.2004,35(2):26.
[19]查旭山.中西医结合“从血论治”治疗寻常型银屑病临床观察.[J]中医药学
刊.2006,24(10):1958-1959.
[20]郭奕妤.采用净屑饮治疗进行期寻常型银屑病30例.[J]广西中医药.2006,29(4):25-26.
[21]贾庆梅.凉血活血消银汤治疗寻常型银屑病40例.[J]天津中医药.2007,24(1):54.
[22]段建伟.张文光.用隔蒜灸治疗银屑病20例. [J]浙江中医杂志.2006,41(10):603.
[23]江长征.用埋线配合穴位注射自血治疗银屑病48例. [J]上海针灸杂志.2006,25(8):28.
[24]聂巧峰.四联法在银屑病治疗中的运用. [J]皮肤病与性病.2006,28(2):26-27.
[25]张丽丽,周飞红.中医药辨证治疗银屑病临床研究现状. [J]中国中西医结合皮肤性病学杂志.2009,8(2):128-129
[26]万静.中西医结合治疗银屑病. [J]吉林医学杂志.2010,31(6):763
[27]徐能.凉血解毒中药治疗银屑病的实验研究. [J]上海中医药大学学报.2004,18(2):61-62.
[28]金力,陈凯. CD34在寻常型银屑病中医辨证分型皮损中的表达. [J]中国皮肤性病学杂志.2006,20(5):273-275.
[29]范斌,李斌.凉血和活血中药对银屑病患者不同时期细胞因子的影响. [J]上海中医药杂志.2006,40(10):34-35.
[30]姜建峰,曹双林.用银杏石榴煎观察对进行期寻常性银屑病患者血小板活化因子及其受体表达水平的影响. [J]中华皮肤科杂志.2007,40(10):640-642.
[31]李斌,王婕.中医"血分论治"对寻常型银屑病患者外周血单个核细胞IFN-γ、IL-4表达影响的实验研究. [J]上海中医药杂志.2007,41(11):5-6.
[32]单筠筠.银屑1号治疗寻常型银屑病临床疗效观察及相关细胞因子检测. [J]中国中西医结合皮肤性病学杂志.2006,5(2):87-88.
[33]王禾.凉血活血胶囊治疗血热型银屑病的临床观察及外周血淋巴细胞亚群检测. [J]中国皮肤性病学杂志.2004,18(3):176.
[34]徐丽敏.血热型/血燥型银屑病患者外周血T淋巴细胞亚群变化. [J]中华皮肤科杂志.2006,39(10):600-601.
[35]张学军银屑病.皮肤性病学.第6版.人民卫生出版社2005:129-133.
[36]郑敏.银屑病的发病机制和治疗的最新进展.2009全国中西医结合皮肤性病学术会议论文汇编.7-8
[37]魏娟.银屑病的发病机制与临床诊断进展. [J]黑龙江医学.2005,29(5):344-346.
[38]瞿幸,张晓芳.白庀[A].见:王永炎.王沛主编.今日中医外科[M]北京:人民卫生出版社.2000.376.
[39] Henseler T,Christophers E.Psoriasis of early and later onset: characterization of two types of p- soriasis vulgaris[J].JAm Acad Dermatol,1985, 13: 450-456.
[40]刘涛峰,张学军,杨森等.银屑病遗传流行病学初步分析.[J]安徽医科大学学报,1998,33(5):354-355.
[41]李敬,徐丽敏,毛舒和.银屑病易感基因位点PSORS1的研究进展[J]中国中西医结合皮肤性病学杂志.2004,3(4):250-253.
[42] Mallon E, BunceM, Savoie H, etal. HLA-Candgullate psoriadis. [J].Br J Dernatol,2000,143: 1177-1182.
[43] O Brien KP,Holm S J,Nilsson S,et al.The HCR gene on 6p21 is unliely to be a psoriasis susceptility gene. [J].JIn2Vest Dermatol,2001,116:750-754.
[44]何平平,杨森,王再兴等.染色体4q存在中国汉族人的银屑病易感基因. [J]中华皮肤科杂志.2003,36 (3):121-123.
[45]高敏,张学军,魏生才等. HLA-A26等位基因与银屑病环境危险因素的交互作用. [J]中国麻风皮肤病杂志.2003,19 (1):22-24.
[46]杨桂兰,陈志强,郑家润等. RT2PCR检测人皮肤组织中趋化因子受体基因. [J]临床检验杂志.2003,21(6):348-350.
[47]朱慧琴,吴瑞勤,陈玲娣等.银屑病患者维生素D受体基因多态性与外周血NK细胞、T淋巴细胞亚群分析. [J]临床皮肤科杂志.2003,32(7):382-384.
[48]郝飞,叶庆伯,阎衡等.银屑病患者外周血单一核细胞CTLA4表达及基因多态性分析. [J]中华皮肤科杂志.2003,36(3):124-126.
[49]徐丽敏,李红,王彦红等.超抗原对银屑病患者外周血单一核细胞和colo16细胞株的细胞动力学影响. [J]临床皮肤科杂志,2003,32(9):518-520.
[50]刘雯,赵广,刘玉峰.银屑病患者外周血单一核细胞对链球菌M6蛋白的反应. [J]第四军医大学学报.2003,24(13):1213-1215.
[51]李新华,张开明,康玉英.银屑病患者T细胞对表皮c-mycbcl22及P53蛋白表达影响的实验研究. [J]中华皮肤科杂志.2004,37(3):147-149
[52]朱可建,商惠英,劳力民.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达. [J]中华皮肤科杂志.2003,36(3):142-144.
[53]周武庆,宁双飞,贾卫等.银屑病患者血清中可溶性血小板T细胞活化抗原1的检测. [J]中华皮肤科杂志.2003,36(3):159-160.
[54]何玉清,张锡宝,吴志华等.银屑病患者细胞因子r-干扰素、白介素-4水平的体外研究. [J]临床皮肤科杂志.2002,31(12):762-763
[55]王飞,Griffiths CEM,Kirby B等.自然杀伤细胞和T淋巴细胞在银屑病发病中作用的研究. [J]临床皮肤科杂志,2002,31(8):489-490.
[56]周海燕,郑家润.中性粒细胞在诱导银屑病急性炎症中的作用:中性粒细胞相关的炎症增强环路. [J]国外医学皮肤性病学分册.2001,27(3):170-173
[57]孙军红,方跃明,郑茂荣.银屑病与中性粒细胞趋化因子. [J]国外医学皮肤性病学分册.2000,26(5):271-273.
[58]余传霖,熊思东.分子免疫学. [M]上海:复旦大学出版社,2001.1235-1253.
[59]赵辨.临床皮肤病学. [M]第3版,江苏科学技术出版社,2001.759-765.
[60] Austin LM, 0zawa M, Kikuchi T, et al. The majority of epidermal in psoriatic patients. [J] JInvest Dermatol,1999,113(5):752-759.
[61] Duan H, Kohda T. Interleukin-8-positiveneutro phils in psoriasis. [J] J Dermatol Sci,2001, 26(2):119-124.
[62] Bryan PP, Fred GW, Mark AG. Pathophysiology and treatment of psoriasis. [J].AM J Heaith2Syst Pham, 2000.57:645.
[63] Patsch G, Wagner E, Leeb BF, et al. Up regulation of cytokine receptors sTNF-R55, sTNF-R75 and sL-2R in psoriasis arthritis synovial fluid. [J].J Rheumatol,1998,25:105-110.
[64]冯信忠,陆毅.细胞因子在银屑病非皮损成纤维细胞中的表达.[J]中华皮肤科杂志.2003,36(3):133-135.
[65] Viemann D, Goebeler M, Schmid S, et al. Transcriptional profiling of IKK2 /NF2B and p38 MAP kinasedependent gene expression in TNF-stimulated primary human endothelial cells. [J].Blood, 2004,103:3365-3373.
[66] Lewis AJ, Manning AM. New targets for anti-inflammatory drugs. [J].Curr op inChem Biol,1999,3(4):489-494.
[67] Hases I, Hobbe RM, Romero MR, et al. A role formitogen activated protein kinase activation by integrine in the pathogenesis of psoriasis. [J].J Clin Invest, 2001, 108(4):527-536.
[68] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokine rantes expression. [J].Biochem J,2000, 274(3):689-696.
[69] Wezler C, Kampfer H ,P feilschifter J, et al. Keratinocyte-derived chemotactic cytokines: expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo. [J].Biochem Biophys Res Commum,2000,274(3):689-696.
[70] Oh CJ, Das KM, Gottlieb AB .Treatment with anti-tumor necrosis factor alpha (TNF-alpha)monoclonal activity of dramatically decrease the clinical activity of psoriasis lesions. [J].J Am Acad Dermatol,2000,42(5Ptl):829-830.
[71] Ogilvie Al, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with anti-tumour necrosis factor-alpha antibody clears skin 1esions of psoriasis resistant to treatment with methotrexate. [J].Br J Dermatol,2001,144:587-589.
[72] Chaudhari U ,Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab mono-therapy for plaque-type psoriasis:a randomized trial. [J]. Lancet, 2001, 357:1842-1847.
[73] Keane J ,Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. [J].N Engl J Med, 2001, 345(15):1098-1104.
[74] Nancy J, Olsen C, Michael S, et al. New drugs for rheumatoid arthritis. [J].N Engl J Med,2004,350:2167-2179.
[75] Zeltser R, Valle L, Tanck C, et al. Clinical,histological,and immunophenotypic characteristics of injection site reactions associated with etanercept:a recombinant tumor necrosis factor alpha recepter: Fc fusion Protein. [J].Arch Dermatol, 2001, 137:893-899.
[76] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriasis arthritis and psoriasis: a randomized trial. [J].Lancet,2000, 356(9227):385-390.
[77] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokineRANTES expression. [J].Biochem J,2000, 274(3):689-696.
[78] Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced Leukocyte rolling and adhesion in the skin of VEGF transgenic mice. [J].J Invest Dermatol,1998, 111(1):1.
[79] Lawrence DA. Transforming growth factor-beta; a general reviews. [J].Eur Cytokine Newt,1996, 7:363-374.
[80] Cai JP, Falanga V, Taylor JR, et a1. Transforming growth factorbeta differentially regulors the adhesiveness of normal and psoriatic dermal microvascular endothelial cells for peripheral bloodmononuclear cells. [J].J Invest Dermatol,1992, 98:405-409.
[81] Fierlbeck G, Rasser G, Muller C. Psoriasis induced at the injection site of recmbenant in-terferon gamma.[J] Arcb Dermatol Res 1990, 126:351-355.
[82] Hancock GE, Kaplan G, Cohn ZA. Kerati-nocyte growth regulation by the products of immune cells. J Exp Med 1988, 168:1395-1402.
[83] Delaporte E,Bieber T,Viac J,etto-kines al.Cy epidermique et inflammation cutanee.Ann Dermatol Venereol 1994, 121:836-843
[84] Lee RE, Gaspare AA, Lotze MT, et al. In-terleukin2 and psoriasis. Arcb Dematol 1988, 124:1811-1815.
[85] Psquer P, Pierard GE. Iterliukin-6 and thskin. Int Arch Allergy Immunol 1996, 109:308-317.
[86] Gilletzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNAin psoriasis amodel for neutro-phil migraton and accumulation in vivo. [J] Invest Dermatol 1996, 107:778-782.
[87] Kojima T, Cromie MA, Fisher GJ, et al. GRO- alpha mRNA is selectively overex-prssed in psoriatic epidermis and is reduced by cyclosporin A in vivo,but not in culturedkeratinocytes. [J] Invest Dermatol 1993;101:767-772.
[88] Leng X, Elias JA.Interleukin-11 inhibits macrophage interleukin-12 production. [J] Immunol 1997;159:2161-2168.
[89]黄建国,向吉夫,印道春等. 5-羟色胺在银屑病患者皮损中的表达. [J]中国麻风皮肤病杂志.2003,19(2):119-121.
[90]柳朋生.神经系统、免疫与皮肤的关系. [J]国外医学皮肤性病学分册.1999,25(1):36238.
[91]杜桂芹,常曼丽,王秀云.银屑病患者检测血小板指数及血流变的临床意义. [J]中国微循环,2004,8(3):180-181.
[92]王香兰,张秉正,王俊民等.银屑病中医分型的血流变学及超微结构相关性研究. [J]中国皮肤性病学杂志.2001,15(3):146-148.
[93]夏凯明,葛正义.银屑病患者的甲襞微循环及血液流变学改变.[J]浙江中西医结合杂志. 1999,9(4):259-260.
[94]兰长贵,吴良章,林新渝.泌乳素与免疫和自身免疫性疾病. [ J].国外医学-皮肤性病学分册,1999,25:77-80.
[95]徐娟,贾随旺,钟绮丽等.银屑病皮损细胞凋亡的研究. [J]岭南皮肤性病科杂志.2004,11(2):91-93.
[96] Farber EM, Nickoloff BJ, Recht B, et al. Stress,symmetry,and psoriasis:possible role of neuropeptides. [J].J Am Acad Dermatol,1986,14:305-311.
[97] Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrith-ione. [J].Am J Dermatopathol,2000,22(3):272-276.
[98] Crutchfield CE 3rd,Lewis EJ,Zelickson BD.The highly effective use of topical zinc pyrithione in the treatment of psoriasis:a case report. [J].Dermatol Online J,1997,3(1):3.
[99]罗绍淼,苏禧,范敏,等.吡硫翁锌气雾剂治疗寻常性银屑病. [J]中华皮肤科杂志,2008,41(8):561.
[100]韩凌,方栩,黄琼,等.吡硫翁锌气雾剂治疗寻常性银屑病的多中心、随机、开放试验. [J]中华皮肤科杂志,2008,41(7):478-479.
[101] Gup ta AK, Cherman AM. Efalizumab in the treatment of psoriasis. [J] J CutanMed Surg, 2006, 10 (2):57-68.
[102] Shikiar R, HeffermanM, Langley RG, et al. Adalimumab treatment is associated with imp rovement in health-related quality oflife in psoriasis: patients reported outcomes from aphaseⅡrandomized controlled trial. [J].J Dermatolog Treat, 2007, 18(1):25-31.
[103] Mease P.TNF-alpha therapy in psoriatic arthritis and psoriasis [J]. Ann RheumDis, 2004, 63(7):755-758.
[104] Heiberg MS, Kaufmann C, Rdevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational multicentre study. [J]. Ann Rheum Dis, 2007, 66 (8):1038-1042.
[105] Bandow GD, Koo JY. Narrow-band ultraviolet B radiation: a review of the current literature. [J]. Int J Dermatol, 2004, 43 (8):555-561.
[106] Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Narrowband-UVB irra-diation decreases the production of pro-inflammatory cytokines by stimulated T cells. [J]. Arch Dermatol Res, 2005, 297(1):39-42.
[107]贺红霞,白莉.窄谱中波紫外线治疗寻常性银屑病的疗效观察. [J]中华皮肤科杂志, 2008, 41(3):194-195.
[108] Buske-Kirschbaum A, Kern S, Ebrecht M, et al. A ltered distribution of leukocyte subsets and cytokine p roduction in response to acute psycho social stress in patients with psoriasis vulgaris. [J].Brain Behav Immun, 2007, 21 (1) : 92-99
[109]杨雪琴,李铀,杨光,等.生物反馈放松训练改善银屑病患者自主神经功能的研究. [J]中华皮肤科杂志,1999, 32 (2):132
[110]邵长庚,杨雪琴,彭永年.银屑病防治研究及合理治疗.[M]北京:中国协和医科大学出版社,2006, 248-250.
[111]杨雪琴.银屑病的整体治疗研究. [J]解放军医学杂志.2009,3.34(3):246
[112] Cook PW, Piepkom M, Clegg CH, et a1. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. [J] Ja in Invest 1997, 100:2286-2294.
[113] Carroll JM, Romew MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. [J] Cell 1995, 83:957-968.
[114] Richard WG,Tamara R,Koichiro N,et a1.Inflammatory and hypeproliferative skin disease in mice that express elevated levels ofthe IL-1 receptor(type I)on epidermal keratinocytes. [J] Clin Invest 1996, 98:336-344.
[115] Niekolof BJ,Kunkel SL,Burdick M,et a1.Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a animal mode1. [J] Am J Pathol 1995, 146:580-588
[116] Niekolof BJ , Wrone-Smith T . Dermal injection of T-lymphocyte induces psoriasis. [J] Clin Invest 1996, 98:1695-1696
[117] Schon MP, De unar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. [J] Nat Med 1997, 3:183-188.
[118] Luger TA, Schwarz T.Evidence for an epidermal cytokine network. [J] Iwest Dermatal, 1990, 95( 6, Supp1): 100-l04.
[119] Barker JNW, Mitra RS, Griffiths CEM, et al. Keratinocytes as inatiators of inflammation. [J] Lamcet, 1991, 337:211.
[120]新宇,郑家润.银屑病发病机制的现代概念, [M]国外医学·皮肤性病学分册.1998,24(3):I37-I39.
[121] Gaylarde PM,et al.psoriasiform changes in guinea pig skin from propranolol. [J] Clin exp dermatol,1978,3:157-160
[2] Baker BS. Brent L. Valdimarsson H. Powles AV. al-lmara L. Walker M. Fry L. ls epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?. [J] Br J Dermatol. 1992 Feb; 126(2):105-10.
[3]冯晓刚,耿春霞,吴明明.银屑病中医病因病机文献研究. [J]现代中西医结合杂志. 2009 18 (8):932
[4]李元文,张丰川.专科专病名医临证经验丛书皮肤病. [J]皮肤病. 2002:270-340.
[5]金起凤.消银解毒汤治疗银屑病58例疗效观察.[J]辽宁中医杂志.1983,(6):29-30
[6]周鸣岐.辨证分型治疗银屑病802例.[J]中医杂志.1989,30(5):42
[7]张志礼.皮肤病临床经验四.中国医药科技出版社.2001,115.
[8]顾伯华.外科经验集.[M]上海:上海人民出版社.1977,252.
[9]丁履伸,赵绚德.银屑病的中医治疗.[J]山东中医学院学报.1980,4(4):47-49.
[10]徐国强.银屑病中医证治浅析.[J]世界中医药.2010,5(1):56-57
[11]钟金宝,李仰琪,凉颜酶.中医辨证治疗寻常银屑病96例. [J]江西中医药.2007,38(8):33-34.
[12]王芳.运用清热凉血法治疗血热型进行期寻常型银屑病46例的临临床观察.[J]北京中医.2005,24(5):301-302.
[13]刘靖,查旭山.凉血消银汤治疗进行习期寻常型银屑病(血热证)32例疗效观察.[J]新中医.2006,38(8):28-29.
[14]张建平,董鸿智.消银汤治疗寻常型银屑病血热证52例.[J]陕西中医学院学报.2007,30(1):33,34.
[15]熊波.从瘀证论治稳定期银屑病50例.[J]湖北中医杂志.2004,26(3):44.
[16]刘朝霞.以健脾益肾治疗寻常型静止期银屑病.[J]新疆中医药.2006,24(5):46-47.
[17]周淑维.庄国康教授治疗银屑病经验.[J]中国中西医结合皮肤性病学杂志.2004,3(1):37.
[18]陈丽红.消银汤治疗寻常型银屑病56例.[J]福建中医药.2004,35(2):26.
[19]查旭山.中西医结合“从血论治”治疗寻常型银屑病临床观察.[J]中医药学
刊.2006,24(10):1958-1959.
[20]郭奕妤.采用净屑饮治疗进行期寻常型银屑病30例.[J]广西中医药.2006,29(4):25-26.
[21]贾庆梅.凉血活血消银汤治疗寻常型银屑病40例.[J]天津中医药.2007,24(1):54.
[22]段建伟.张文光.用隔蒜灸治疗银屑病20例. [J]浙江中医杂志.2006,41(10):603.
[23]江长征.用埋线配合穴位注射自血治疗银屑病48例. [J]上海针灸杂志.2006,25(8):28.
[24]聂巧峰.四联法在银屑病治疗中的运用. [J]皮肤病与性病.2006,28(2):26-27.
[25]张丽丽,周飞红.中医药辨证治疗银屑病临床研究现状. [J]中国中西医结合皮肤性病学杂志.2009,8(2):128-129
[26]万静.中西医结合治疗银屑病. [J]吉林医学杂志.2010,31(6):763
[27]徐能.凉血解毒中药治疗银屑病的实验研究. [J]上海中医药大学学报.2004,18(2):61-62.
[28]金力,陈凯. CD34在寻常型银屑病中医辨证分型皮损中的表达. [J]中国皮肤性病学杂志.2006,20(5):273-275.
[29]范斌,李斌.凉血和活血中药对银屑病患者不同时期细胞因子的影响. [J]上海中医药杂志.2006,40(10):34-35.
[30]姜建峰,曹双林.用银杏石榴煎观察对进行期寻常性银屑病患者血小板活化因子及其受体表达水平的影响. [J]中华皮肤科杂志.2007,40(10):640-642.
[31]李斌,王婕.中医"血分论治"对寻常型银屑病患者外周血单个核细胞IFN-γ、IL-4表达影响的实验研究. [J]上海中医药杂志.2007,41(11):5-6.
[32]单筠筠.银屑1号治疗寻常型银屑病临床疗效观察及相关细胞因子检测. [J]中国中西医结合皮肤性病学杂志.2006,5(2):87-88.
[33]王禾.凉血活血胶囊治疗血热型银屑病的临床观察及外周血淋巴细胞亚群检测. [J]中国皮肤性病学杂志.2004,18(3):176.
[34]徐丽敏.血热型/血燥型银屑病患者外周血T淋巴细胞亚群变化. [J]中华皮肤科杂志.2006,39(10):600-601.
[35]张学军银屑病.皮肤性病学.第6版.人民卫生出版社2005:129-133.
[36]郑敏.银屑病的发病机制和治疗的最新进展.2009全国中西医结合皮肤性病学术会议论文汇编.7-8
[37]魏娟.银屑病的发病机制与临床诊断进展. [J]黑龙江医学.2005,29(5):344-346.
[38]瞿幸,张晓芳.白庀[A].见:王永炎.王沛主编.今日中医外科[M]北京:人民卫生出版社.2000.376.
[39] Henseler T,Christophers E.Psoriasis of early and later onset: characterization of two types of p- soriasis vulgaris[J].JAm Acad Dermatol,1985, 13: 450-456.
[40]刘涛峰,张学军,杨森等.银屑病遗传流行病学初步分析.[J]安徽医科大学学报,1998,33(5):354-355.
[41]李敬,徐丽敏,毛舒和.银屑病易感基因位点PSORS1的研究进展[J]中国中西医结合皮肤性病学杂志.2004,3(4):250-253.
[42] Mallon E, BunceM, Savoie H, etal. HLA-Candgullate psoriadis. [J].Br J Dernatol,2000,143: 1177-1182.
[43] O Brien KP,Holm S J,Nilsson S,et al.The HCR gene on 6p21 is unliely to be a psoriasis susceptility gene. [J].JIn2Vest Dermatol,2001,116:750-754.
[44]何平平,杨森,王再兴等.染色体4q存在中国汉族人的银屑病易感基因. [J]中华皮肤科杂志.2003,36 (3):121-123.
[45]高敏,张学军,魏生才等. HLA-A26等位基因与银屑病环境危险因素的交互作用. [J]中国麻风皮肤病杂志.2003,19 (1):22-24.
[46]杨桂兰,陈志强,郑家润等. RT2PCR检测人皮肤组织中趋化因子受体基因. [J]临床检验杂志.2003,21(6):348-350.
[47]朱慧琴,吴瑞勤,陈玲娣等.银屑病患者维生素D受体基因多态性与外周血NK细胞、T淋巴细胞亚群分析. [J]临床皮肤科杂志.2003,32(7):382-384.
[48]郝飞,叶庆伯,阎衡等.银屑病患者外周血单一核细胞CTLA4表达及基因多态性分析. [J]中华皮肤科杂志.2003,36(3):124-126.
[49]徐丽敏,李红,王彦红等.超抗原对银屑病患者外周血单一核细胞和colo16细胞株的细胞动力学影响. [J]临床皮肤科杂志,2003,32(9):518-520.
[50]刘雯,赵广,刘玉峰.银屑病患者外周血单一核细胞对链球菌M6蛋白的反应. [J]第四军医大学学报.2003,24(13):1213-1215.
[51]李新华,张开明,康玉英.银屑病患者T细胞对表皮c-mycbcl22及P53蛋白表达影响的实验研究. [J]中华皮肤科杂志.2004,37(3):147-149
[52]朱可建,商惠英,劳力民.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达. [J]中华皮肤科杂志.2003,36(3):142-144.
[53]周武庆,宁双飞,贾卫等.银屑病患者血清中可溶性血小板T细胞活化抗原1的检测. [J]中华皮肤科杂志.2003,36(3):159-160.
[54]何玉清,张锡宝,吴志华等.银屑病患者细胞因子r-干扰素、白介素-4水平的体外研究. [J]临床皮肤科杂志.2002,31(12):762-763
[55]王飞,Griffiths CEM,Kirby B等.自然杀伤细胞和T淋巴细胞在银屑病发病中作用的研究. [J]临床皮肤科杂志,2002,31(8):489-490.
[56]周海燕,郑家润.中性粒细胞在诱导银屑病急性炎症中的作用:中性粒细胞相关的炎症增强环路. [J]国外医学皮肤性病学分册.2001,27(3):170-173
[57]孙军红,方跃明,郑茂荣.银屑病与中性粒细胞趋化因子. [J]国外医学皮肤性病学分册.2000,26(5):271-273.
[58]余传霖,熊思东.分子免疫学. [M]上海:复旦大学出版社,2001.1235-1253.
[59]赵辨.临床皮肤病学. [M]第3版,江苏科学技术出版社,2001.759-765.
[60] Austin LM, 0zawa M, Kikuchi T, et al. The majority of epidermal in psoriatic patients. [J] JInvest Dermatol,1999,113(5):752-759.
[61] Duan H, Kohda T. Interleukin-8-positiveneutro phils in psoriasis. [J] J Dermatol Sci,2001, 26(2):119-124.
[62] Bryan PP, Fred GW, Mark AG. Pathophysiology and treatment of psoriasis. [J].AM J Heaith2Syst Pham, 2000.57:645.
[63] Patsch G, Wagner E, Leeb BF, et al. Up regulation of cytokine receptors sTNF-R55, sTNF-R75 and sL-2R in psoriasis arthritis synovial fluid. [J].J Rheumatol,1998,25:105-110.
[64]冯信忠,陆毅.细胞因子在银屑病非皮损成纤维细胞中的表达.[J]中华皮肤科杂志.2003,36(3):133-135.
[65] Viemann D, Goebeler M, Schmid S, et al. Transcriptional profiling of IKK2 /NF2B and p38 MAP kinasedependent gene expression in TNF-stimulated primary human endothelial cells. [J].Blood, 2004,103:3365-3373.
[66] Lewis AJ, Manning AM. New targets for anti-inflammatory drugs. [J].Curr op inChem Biol,1999,3(4):489-494.
[67] Hases I, Hobbe RM, Romero MR, et al. A role formitogen activated protein kinase activation by integrine in the pathogenesis of psoriasis. [J].J Clin Invest, 2001, 108(4):527-536.
[68] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokine rantes expression. [J].Biochem J,2000, 274(3):689-696.
[69] Wezler C, Kampfer H ,P feilschifter J, et al. Keratinocyte-derived chemotactic cytokines: expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo. [J].Biochem Biophys Res Commum,2000,274(3):689-696.
[70] Oh CJ, Das KM, Gottlieb AB .Treatment with anti-tumor necrosis factor alpha (TNF-alpha)monoclonal activity of dramatically decrease the clinical activity of psoriasis lesions. [J].J Am Acad Dermatol,2000,42(5Ptl):829-830.
[71] Ogilvie Al, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with anti-tumour necrosis factor-alpha antibody clears skin 1esions of psoriasis resistant to treatment with methotrexate. [J].Br J Dermatol,2001,144:587-589.
[72] Chaudhari U ,Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab mono-therapy for plaque-type psoriasis:a randomized trial. [J]. Lancet, 2001, 357:1842-1847.
[73] Keane J ,Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. [J].N Engl J Med, 2001, 345(15):1098-1104.
[74] Nancy J, Olsen C, Michael S, et al. New drugs for rheumatoid arthritis. [J].N Engl J Med,2004,350:2167-2179.
[75] Zeltser R, Valle L, Tanck C, et al. Clinical,histological,and immunophenotypic characteristics of injection site reactions associated with etanercept:a recombinant tumor necrosis factor alpha recepter: Fc fusion Protein. [J].Arch Dermatol, 2001, 137:893-899.
[76] Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriasis arthritis and psoriasis: a randomized trial. [J].Lancet,2000, 356(9227):385-390.
[77] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokineRANTES expression. [J].Biochem J,2000, 274(3):689-696.
[78] Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced Leukocyte rolling and adhesion in the skin of VEGF transgenic mice. [J].J Invest Dermatol,1998, 111(1):1.
[79] Lawrence DA. Transforming growth factor-beta; a general reviews. [J].Eur Cytokine Newt,1996, 7:363-374.
[80] Cai JP, Falanga V, Taylor JR, et a1. Transforming growth factorbeta differentially regulors the adhesiveness of normal and psoriatic dermal microvascular endothelial cells for peripheral bloodmononuclear cells. [J].J Invest Dermatol,1992, 98:405-409.
[81] Fierlbeck G, Rasser G, Muller C. Psoriasis induced at the injection site of recmbenant in-terferon gamma.[J] Arcb Dermatol Res 1990, 126:351-355.
[82] Hancock GE, Kaplan G, Cohn ZA. Kerati-nocyte growth regulation by the products of immune cells. J Exp Med 1988, 168:1395-1402.
[83] Delaporte E,Bieber T,Viac J,etto-kines al.Cy epidermique et inflammation cutanee.Ann Dermatol Venereol 1994, 121:836-843
[84] Lee RE, Gaspare AA, Lotze MT, et al. In-terleukin2 and psoriasis. Arcb Dematol 1988, 124:1811-1815.
[85] Psquer P, Pierard GE. Iterliukin-6 and thskin. Int Arch Allergy Immunol 1996, 109:308-317.
[86] Gilletzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNAin psoriasis amodel for neutro-phil migraton and accumulation in vivo. [J] Invest Dermatol 1996, 107:778-782.
[87] Kojima T, Cromie MA, Fisher GJ, et al. GRO- alpha mRNA is selectively overex-prssed in psoriatic epidermis and is reduced by cyclosporin A in vivo,but not in culturedkeratinocytes. [J] Invest Dermatol 1993;101:767-772.
[88] Leng X, Elias JA.Interleukin-11 inhibits macrophage interleukin-12 production. [J] Immunol 1997;159:2161-2168.
[89]黄建国,向吉夫,印道春等. 5-羟色胺在银屑病患者皮损中的表达. [J]中国麻风皮肤病杂志.2003,19(2):119-121.
[90]柳朋生.神经系统、免疫与皮肤的关系. [J]国外医学皮肤性病学分册.1999,25(1):36238.
[91]杜桂芹,常曼丽,王秀云.银屑病患者检测血小板指数及血流变的临床意义. [J]中国微循环,2004,8(3):180-181.
[92]王香兰,张秉正,王俊民等.银屑病中医分型的血流变学及超微结构相关性研究. [J]中国皮肤性病学杂志.2001,15(3):146-148.
[93]夏凯明,葛正义.银屑病患者的甲襞微循环及血液流变学改变.[J]浙江中西医结合杂志. 1999,9(4):259-260.
[94]兰长贵,吴良章,林新渝.泌乳素与免疫和自身免疫性疾病. [ J].国外医学-皮肤性病学分册,1999,25:77-80.
[95]徐娟,贾随旺,钟绮丽等.银屑病皮损细胞凋亡的研究. [J]岭南皮肤性病科杂志.2004,11(2):91-93.
[96] Farber EM, Nickoloff BJ, Recht B, et al. Stress,symmetry,and psoriasis:possible role of neuropeptides. [J].J Am Acad Dermatol,1986,14:305-311.
[97] Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrith-ione. [J].Am J Dermatopathol,2000,22(3):272-276.
[98] Crutchfield CE 3rd,Lewis EJ,Zelickson BD.The highly effective use of topical zinc pyrithione in the treatment of psoriasis:a case report. [J].Dermatol Online J,1997,3(1):3.
[99]罗绍淼,苏禧,范敏,等.吡硫翁锌气雾剂治疗寻常性银屑病. [J]中华皮肤科杂志,2008,41(8):561.
[100]韩凌,方栩,黄琼,等.吡硫翁锌气雾剂治疗寻常性银屑病的多中心、随机、开放试验. [J]中华皮肤科杂志,2008,41(7):478-479.
[101] Gup ta AK, Cherman AM. Efalizumab in the treatment of psoriasis. [J] J CutanMed Surg, 2006, 10 (2):57-68.
[102] Shikiar R, HeffermanM, Langley RG, et al. Adalimumab treatment is associated with imp rovement in health-related quality oflife in psoriasis: patients reported outcomes from aphaseⅡrandomized controlled trial. [J].J Dermatolog Treat, 2007, 18(1):25-31.
[103] Mease P.TNF-alpha therapy in psoriatic arthritis and psoriasis [J]. Ann RheumDis, 2004, 63(7):755-758.
[104] Heiberg MS, Kaufmann C, Rdevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational multicentre study. [J]. Ann Rheum Dis, 2007, 66 (8):1038-1042.
[105] Bandow GD, Koo JY. Narrow-band ultraviolet B radiation: a review of the current literature. [J]. Int J Dermatol, 2004, 43 (8):555-561.
[106] Sigmundsdottir H, Johnston A, Gudjonsson JE, et al. Narrowband-UVB irra-diation decreases the production of pro-inflammatory cytokines by stimulated T cells. [J]. Arch Dermatol Res, 2005, 297(1):39-42.
[107]贺红霞,白莉.窄谱中波紫外线治疗寻常性银屑病的疗效观察. [J]中华皮肤科杂志, 2008, 41(3):194-195.
[108] Buske-Kirschbaum A, Kern S, Ebrecht M, et al. A ltered distribution of leukocyte subsets and cytokine p roduction in response to acute psycho social stress in patients with psoriasis vulgaris. [J].Brain Behav Immun, 2007, 21 (1) : 92-99
[109]杨雪琴,李铀,杨光,等.生物反馈放松训练改善银屑病患者自主神经功能的研究. [J]中华皮肤科杂志,1999, 32 (2):132
[110]邵长庚,杨雪琴,彭永年.银屑病防治研究及合理治疗.[M]北京:中国协和医科大学出版社,2006, 248-250.
[111]杨雪琴.银屑病的整体治疗研究. [J]解放军医学杂志.2009,3.34(3):246
[112] Cook PW, Piepkom M, Clegg CH, et a1. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. [J] Ja in Invest 1997, 100:2286-2294.
[113] Carroll JM, Romew MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. [J] Cell 1995, 83:957-968.
[114] Richard WG,Tamara R,Koichiro N,et a1.Inflammatory and hypeproliferative skin disease in mice that express elevated levels ofthe IL-1 receptor(type I)on epidermal keratinocytes. [J] Clin Invest 1996, 98:336-344.
[115] Niekolof BJ,Kunkel SL,Burdick M,et a1.Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a animal mode1. [J] Am J Pathol 1995, 146:580-588
[116] Niekolof BJ , Wrone-Smith T . Dermal injection of T-lymphocyte induces psoriasis. [J] Clin Invest 1996, 98:1695-1696
[117] Schon MP, De unar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. [J] Nat Med 1997, 3:183-188.
[118] Luger TA, Schwarz T.Evidence for an epidermal cytokine network. [J] Iwest Dermatal, 1990, 95( 6, Supp1): 100-l04.
[119] Barker JNW, Mitra RS, Griffiths CEM, et al. Keratinocytes as inatiators of inflammation. [J] Lamcet, 1991, 337:211.
[120]新宇,郑家润.银屑病发病机制的现代概念, [M]国外医学·皮肤性病学分册.1998,24(3):I37-I39.
[121] Gaylarde PM,et al.psoriasiform changes in guinea pig skin from propranolol. [J] Clin exp dermatol,1978,3:157-160